# First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

Source: https://onco.cc/trials/nct05141149/  
OnCo record `nct05141149` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Prestige Biopharma Limited, active and no longer recruiting.

## Summary

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05141149 by Prestige Biopharma Limited, with 80 participants enrolled, started 2023-06-05 and due to reach its primary completion in 2026-07. Interventions recorded: PBP1510 (400mg/16mL) and Gemcitabine (1000 mg/m^2).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05141149
- Phase: 1/2
- Setting: A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer
- Sponsor: Prestige Biopharma Limited
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT05141149: https://clinicaltrials.gov/study/NCT05141149

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [PBP1510](https://onco.cc/drugs/pbp1510/)

---
JSON: https://onco.cc/api/v1/entities/nct05141149.json